Skip to main content
. 2016 Feb 2;39(2):77–86. doi: 10.14348/molcells.2016.2350

Fig. 3.

Fig. 3.

In vivo drug efficacy testing of combination therapy using PDX models. Combination effects of BCL2L1 inhibitor (ABT-737) and cytotoxic drug (irinotecan) were tested in BCL2L1-amplified (11 copies) gastric cancer PDX models. Average tumor sizes of treated groups are plotted (left panel) and representative tumors after treatment are shown (right panel). Scale bar: 10 mm. (reproduced from Park et al., 2015).